Richard L. Wahl, M.D. is Professor of Radiology and Oncology, as well as the Henry N. Wagner, Jr. Professor of Nuclear Medicine at Johns Hopkins University School of Medicine in Baltimore, MD. He is Director of Nuclear Medicine, PET and the Vice Chair of Radiology for Technology and New Business Development. Dr. Wahl received his MD degree at Washington University in St. Louis, served as medical intern at the University of California, San Diego, and had residencey/fellowship training in Radiology and Nuclear Medicine at the Mallinckrodt Institute of Radiology and immunology training in the Howard Hughes Immunology Laboratories at Washington University. He has contributed extensively to the development of FDG PET imaging in oncology in both preclinical and clinical studies showing the feasibility of the method in both cancer diagnosis, staging and treatment response in a wide range of cancers. He and his colleague Chuck Meyer developed anatometabolic image fusion, fusion of PET with CT , SPECT or MRI into hybrid images of cancer . He also is one of the inventors of radioimmunotherapy of lymphoma with anti CD20 antibodies, methods underlying FDA approved radioimmunotherapies. He has also been an inventor of FDA approved medical devices such as radionuclide guided biopsy. He and his colleagues have published approximately 350 articles and several books on PET, PET/CT and SPECT/CT He has received a variety of professional honors and has delivered multiple named lectureships including The New Horizons Lecture at the RSNA, the Marie Curie Lecture at the EANM, and the Henry Wanger lecture at the SNM. He has received the Berson and Yalow and Tetalman Awards from the SNM, the Hounsfield Award from the Society of Body CT and MRI, The Distinguished Scientist Awards from the AMI, the “Most Outstanding Radiology Researcher” from “Aunt Minnie. He has served a chairman of the board of the ABNM, president of the ICP, program and refresher course chair for RSNA, on multiple NIH and other study sections, and on the CMS MCAC panel. Recently he and his colleagues proposed the “PERCIST” criteria for PET assessment of cancer treatment response, the focus of his FDA presentation at this meeting.